# Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

> **NCT00563381** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 7376 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium bromide
- **DRUG:** Salmeterol
- **DRUG:** Placebo Salmeterol
- **DRUG:** Placebo Tiotropium

## Key facts

- **NCT ID:** NCT00563381
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 7376 (ACTUAL)
- **Last updated:** 2013-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563381, "Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00563381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*